Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 77 Neoplasms 69 Prostatic Neoplasms 51 Colorectal Neoplasms 44 Lung Neoplasms 38 Carcinoma, Non-Small-Cell Lung 28 Hematologic Neoplasms 22 Pancreatic Neoplasms 21 Neoplasm Metastasis 20 Head and Neck Neoplasms 19 Urinary Bladder Neoplasms 15 Ovarian Neoplasms 15 Multiple Myeloma 15 Stomach Neoplasms 11 Squamous Cell Carcinoma of Head and Neck 11 Motor Activity 11 Leukemia, Myeloid, Acute 11 Glioblastoma 10 Uterine Cervical Neoplasms 9 Triple Negative Breast Neoplasms 9 Gastrointestinal Neoplasms 9 Colonic Neoplasms 9 Melanoma 8 Hematopoietic and Lymphatic System Neoplasm 8 Glioma 8 Esophageal Neoplasms 8 Carcinoma, Renal Cell 8 COVID-19 8 Anxiety Disorders 8 Anatomic Stage I Breast Cancer AJCC v8 8

Interventions

Nivolumab 3 Cisplatin 2 Albumin-Bound Paclitaxel 2 tislelizumab 1 spartalizumab 1 Taxes 1 Standard of Care 1 Radiotherapy 1 Neoadjuvant Therapy 1 Immunotherapy 1 Gemcitabine 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Muscle-Invasive Bladder Carcinoma × Standard of Care × Clear all

NCT04724928 2025-01-15

EFFORT-MIBC

University Hospital, Ghent

Phase 2 Recruiting

Muscle-Invasive Bladder Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡